Analysts Set 4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) Target Price at $45.25

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT) has been given an average rating of “Moderate Buy” by the ten brokerages that are currently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average 1-year price target among brokers that have issued ratings on the stock in the last year is $45.25.

FDMT has been the topic of several research analyst reports. Royal Bank of Canada reissued an “outperform” rating and set a $40.00 target price on shares of 4D Molecular Therapeutics in a research note on Monday, July 22nd. HC Wainwright reissued a “buy” rating and set a $36.00 price objective on shares of 4D Molecular Therapeutics in a research report on Thursday, September 19th. Cantor Fitzgerald lowered 4D Molecular Therapeutics from an “overweight” rating to a “neutral” rating in a research report on Monday, September 23rd. BMO Capital Markets cut their price target on 4D Molecular Therapeutics from $63.00 to $40.00 and set an “outperform” rating on the stock in a report on Thursday, July 18th. Finally, Chardan Capital boosted their price objective on 4D Molecular Therapeutics from $38.00 to $39.00 and gave the company a “buy” rating in a report on Thursday, September 19th.

Insider Buying and Selling at 4D Molecular Therapeutics

In other news, CEO David Kirn sold 12,923 shares of the company’s stock in a transaction on Wednesday, July 10th. The shares were sold at an average price of $22.49, for a total value of $290,638.27. Following the completion of the sale, the chief executive officer now owns 1,059,153 shares in the company, valued at approximately $23,820,350.97. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. In related news, insider Scott Bizily sold 1,996 shares of the stock in a transaction that occurred on Thursday, July 11th. The stock was sold at an average price of $25.00, for a total transaction of $49,900.00. Following the completion of the sale, the insider now directly owns 6,781 shares of the company’s stock, valued at $169,525. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO David Kirn sold 12,923 shares of the business’s stock in a transaction on Wednesday, July 10th. The stock was sold at an average price of $22.49, for a total value of $290,638.27. Following the completion of the transaction, the chief executive officer now directly owns 1,059,153 shares in the company, valued at approximately $23,820,350.97. The disclosure for this sale can be found here. In the last three months, insiders have sold 21,417 shares of company stock worth $486,883. Corporate insiders own 7.30% of the company’s stock.

Institutional Investors Weigh In On 4D Molecular Therapeutics

Hedge funds have recently made changes to their positions in the business. Healthcare of Ontario Pension Plan Trust Fund increased its holdings in 4D Molecular Therapeutics by 10.1% during the second quarter. Healthcare of Ontario Pension Plan Trust Fund now owns 706,000 shares of the company’s stock worth $14,819,000 after buying an additional 65,000 shares during the last quarter. Algert Global LLC grew its position in shares of 4D Molecular Therapeutics by 20.6% during the 2nd quarter. Algert Global LLC now owns 16,588 shares of the company’s stock valued at $348,000 after acquiring an additional 2,828 shares during the period. The Manufacturers Life Insurance Company increased its stake in shares of 4D Molecular Therapeutics by 25.5% during the 2nd quarter. The Manufacturers Life Insurance Company now owns 18,975 shares of the company’s stock worth $398,000 after purchasing an additional 3,850 shares during the last quarter. Squarepoint Ops LLC increased its stake in shares of 4D Molecular Therapeutics by 652.7% during the 2nd quarter. Squarepoint Ops LLC now owns 110,041 shares of the company’s stock worth $2,310,000 after purchasing an additional 95,422 shares during the last quarter. Finally, Hsbc Holdings PLC bought a new stake in shares of 4D Molecular Therapeutics in the 2nd quarter worth approximately $246,000. 99.27% of the stock is currently owned by institutional investors.

4D Molecular Therapeutics Trading Down 1.2 %

NASDAQ:FDMT opened at $10.83 on Monday. The stock’s 50-day moving average is $15.21 and its 200-day moving average is $21.98. 4D Molecular Therapeutics has a 1-year low of $9.44 and a 1-year high of $36.25. The stock has a market cap of $562.84 million, a P/E ratio of -4.44 and a beta of 2.80.

4D Molecular Therapeutics (NASDAQ:FDMT) last posted its quarterly earnings data on Thursday, August 8th. The company reported ($0.63) EPS for the quarter, topping analysts’ consensus estimates of ($0.72) by $0.09. The company had revenue of $0.01 million during the quarter, compared to analyst estimates of $1.90 million. As a group, equities analysts forecast that 4D Molecular Therapeutics will post -2.75 EPS for the current year.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.